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•  Group	   of	   chronic	   and	   progressive	   diseases	   characterized	   by	  
symmetric	  and	  selec8ve	  loss	  of	  the	  neurons	  in	  motor,	  sensory	  
or	  cogni8ve	  systems	  	  
•  They	   cause	   abnormali8es	   in	   the	   transport,	   degrada8on	   and	  
aggrega8on	  of	  proteins	  that	  lead	  to	  cell-­‐specific	  changes	  	  
•  Common	   in	  all	   the	  neurodegenera8ve	  diseases	   is	   the	  cell	   loss	  
and	  intraneuronal	  accumula8ons	  of	  fibrillary	  materials	  	  
Search	  in	  PubMed	  and	  Medline	  for	  ar8cles	  published	  between	  January	  1,	  2005	  and	  December	  31,	  2012.	  No	  language	  restric8on.	  Search	  terms	  “Tau	  protein”,	  “tau	  neurodegenera8on”,	  “tauopathies”,	  “tau	  gene”	  and	  “tau	  pathology”	  in	  addi8on	  to	  disease-­‐specific	  terms.	  	  
	  
•  Tau	   are	   low	   molecular	   weight	   proteins	   whose	   func8on	   is	   the	  
assembly	   and	   stabiliza8on	   of	   microtubules,	   and	   they	   play	   a	   key	  
role	   in	   the	   anterograde	   transport	   by	   kinesin	   and	   retrograde	  
transport	  by	  dyneins.	  	  
•  Abundant	   in	   the	  central	  nervous	   system,	  expressed	  mainly	   in	   the	  
axons,	   although	   they	   can	   be	   also	   found	   on	   the	   axons	   of	   the	  
peripheral	  nervous	  system.	  	  
PICK’S	  DISEASE	  
CLASSIFICATION	  
Alterna8ve	  names	   Microscopic	  features	   Gross	  Brain	  Features	  
Type	  A	   Classic	  Pick’s	  Disease	   Presence	   of	   both	   Pick	   bodies	   and	  
Pick	  cells	  
Prominent	   frontotemporal	   and	   limbic	  
degenera8on	  
Type	  B	   Frontotemporal	   demen8a	   with	  
P a r k i n s o n i s m	   l i n k e d	   t o	  
chromosome	  17	  
Absence	   of	   P ick	   bodies	   and	  
numerous	  Pick	  cells	  
Superior	   frontal	   and	   parietal	   lobes	  
degenera8on	  
Type	  C	   Demen8a	   lacking	   dis8nc8ve	  
histopathology	  
Neither	  Pick	  bodies	  nor	  Pick	  cells	   General	  cor8cal	  degenera8on	  
Table	  2:	  Tissot,	  Constan8nidis	  and	  Richard’s	  classifica8on	  of	  Pick’s	  disease	  based	  in	  their	  gross	  and	  microscopic	  features.	  
•  3R	   –	   Tauopathy	   first	   described	   by	   Arnold	  
Pick.	  Onset	  age	  <	  65	  years	  old.	  
•  Characterized	  by	  behavioural	  changes	  such	  
as	   desinibi8on,	   language	   problems,	  
extrapyramidal	  signs	  and	  aphasia.	  Execu8ve	  
func8ons ,	   such	   a s	   p l ann ing	   and	  
organiza8on,	  may	   become	   impaired,	  while	  
memory,	   orienta8on	   and	   visual-­‐spa8al	  
func8on	  are	  preserved.	  	  
•  Asymmetric	   frontotemporal	   atrophy	   that	  
affects	  more	   the	   leZ	   hemisphere	   than	   the	  
right,	   atrophy	   of	   the	   bilateral	   caudate	  
nuclei	  and	  evident	  reduc8on	  in	  perfusion	  of	  
frontal	  and	  temporal	  lobes	  
CORTICOBASAL	  DEGENERATION	  
•  Rare	   progressive	   neurodegenera8ve	   4R-­‐
tauopathy	  associated	  with	  a	  wide	  variety	  of	  
motor,	   sensory,	   behavioral	   and	   cogni8ve	  
symptoms.	  
•  Complicated	   clinical	   diagnosis	   due	   to	   the	  
var iabi l i ty	   of	   presenta8on	   of	   true	  
cor8cobasa l	   degenera8on	   and	   the	  
syndromes	  that	  look	  like	  it	  but	  are	  caused	  by	  
other	   neurodegenera8ve	   diseases	   	   (CBD	  
mimickers)	  
•  Gradual	   progression:	   From	   unilateral	   to	  
affect	  both	  hemispheres	  
	  
•  It	   is	   characterized	   by	   the	   presence	   of	   amyloid	   plaques,	   intracellular	  
neurofibrillary	  tangles	  (NFT)	  and	  oxida8ve	  stress	  
•  The	  amyloid	  plaques	  (or	  senile	  plaques)	  are	  extracellular	  deposits	  of	  
aggregated	  β-­‐amyloid	  pep8des	  (Aβ)	  typically	  surrounded	  by	  neurons	  
with	  dystrophic	  neurites	  
•  Neurofibrillary	   tangles	   (NFTs)	   are	   generally	   intraneuronal	  
cytoplasma8c	   bundles	   of	   paired	   helical	   filaments	   (PHFs),	   whose	  
subunit	  protein	  is	  Tau	  (3R	  and	  4R	  isoforms)	  
•  No	  treatment	  to	  stop	  	  AD	  neurodegenera8on,	  just	  to	  slow	  its	  progression	  
•  Three	  transgenic	  mice	  models	  have	  been	  developed:	  
1.  Aβ-­‐pathology	  model	  
2.  Tau-­‐pathology	  model	  
3.  Triple	  –	  transgenic	  model:	  muta8ons	  in	  APP,	  PSEN1	  and	  
MAPT	  






Figure	  4:	  Process	  of	  Tau	  	  aggrega8on.	  Adapted	  from	  Mar8n	  et	  Al.	  2011.	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TAU	  PROTEIN	  
MATERIALS	  AND	  METHODS	  
Figure	   1:	   (1)	   Tau	   gene	  
structure	   and	   adult	  
human	  isoforms.	  
	  	  
(2)	  Parts	  of	   tau	  protein.	  
Adapted	   from	   Buée	   et	  
Al.	  2000	  
Figure	   2:	   	   Connec8ons	  
between	   tau	   post-­‐
t r a n s l a 8 o n a l	  
mod i fi c a 8 o n s	   a n d	  
r e gu l a8on	   o f	   NFT	  
f o rma8on .	   	   UPS :	  
ubiqui8n–proteasome	  
system.	   Adapted	   from	  
Mar8n	  et	  Al.	  2011	  
	  
REFERENCES	  
TAU	  BASED	  THERAPIES	  
•  Three	  therapies	  are	  in	  clinical	  phases	  of	  development	  (Gotz	  et	  Al.2012)	  :	  
•  Methylene	  blue:	  Inhibits	  tau	  aggrega8on	  by	  introducing	  into	  the	  
structure	  of	  paired-­‐helical	  filaments	  and	  destabilizes	  them.	  
	  
•  Lithium	  chloride:	  Inhibidor	  of	  GSK3,	  one	  of	  the	  kinases	  that	  
phosphorylates	  tau.	  Therefore,	  it	  inhibits	  tau	  aggrega8on.	  
	  
•  Neuroprotec8ve	  octapep8de	  NAP:	  Microtubule	  –	  stabilizing	  
compound	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Figure	  5:	  Neuropathological	  changes	   in	  Pick	  disease.	   (A1)	   Loss	  of	  neurons	  of	  
pigmented	   brain	   stem	   nuclei.	   (A2)	   Lewy	   bodies	   with	   bizarre	  morphology	   in	  
dorsal	   nucleus	   of	   vagal	   nerve.	   (A3)	   Lewy	   bodies	   are	   immunoreac8ve	   of	   a-­‐
synuclein.	   (B1)	   Neuronal	   loss	   and	   gliosis.	   Hematoxilin	   and	   Eosin	   Stain.	   (B2)	  
Ballooned	  neurons	  or	  Pick	  Cells	  (B3)	  Neurons	  containing	  basophilic	  inclusions	  
or	  Pick-­‐Bodies.	  Adapted	  from	  Vilas	  et	  Al	  2012.	  
Figure	   6:	   	   Histological	   features	   of	   Cor8cobasal	   degenera8on.	   (a)Marked	  
neuronal	   loss,	   astrogliosis	   and	   spongiosis	   in	   H-­‐E	   stained	   sec8ons	   of	   the	  
parietal	  cortex	  (b)	  together	  with	  some	  ballooned	  cells.	  (c)Cor8cal	  AT8	  stained	  
astrocy8c	   plaques.	   (d)	   Neuronal	   tau	   pathology.	   Adapted	   from	   Jung	   et	   Al.	  
2012. 
